CRISPR Therapeutics AG (CRISPR Therapeutics AG) Scaled Net Operating Assets : 0.09 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is CRISPR Therapeutics AG Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

CRISPR Therapeutics AG's operating assets for the quarter that ended in Mar. 2024 was $330.9 Mil. CRISPR Therapeutics AG's operating liabilities for the quarter that ended in Mar. 2024 was $120.2 Mil. CRISPR Therapeutics AG's Total Assets for the quarter that ended in Dec. 2023 was $2,229.6 Mil. Therefore, CRISPR Therapeutics AG's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.09.

CRISPR Therapeutics AG Scaled Net Operating Assets Historical Data

The historical data trend for CRISPR Therapeutics AG's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Scaled Net Operating Assets Chart

CRISPR Therapeutics AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.10

0.03

0.13

0.11

0.19

CRISPR Therapeutics AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.10	0.13	0.10	0.21	0.10

Competitive Comparison of CRISPR Therapeutics AG's Scaled Net Operating Assets

For the Biotechnology subindustry, CRISPR Therapeutics AG's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CRISPR Therapeutics AG's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Scaled Net Operating Assets falls into.

CRISPR Therapeutics AG Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

CRISPR Therapeutics AG's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(535.879	-	108.136)	/	2243.057
=	0.19

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	2229.571	-	1693.692
=	535.879

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	346.768	-	223.007	-	15.625
=	108.136

CRISPR Therapeutics AG's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2024 )
=	(Operating Assets (Q: Mar. 2024 )	-	Operating Liabilities (Q: Mar. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(330.892	-	120.154)	/	2229.571
=	0.09

where

	Operating Assets		(Q: Mar. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	2439.017	-	2108.125
=	330.892

	Operating Liabilities		(Q: Mar. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	355.081	-	218.935	-	15.992
=	120.154

CRISPR Therapeutics AG Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

CRISPR Therapeutics AG (CRISPR Therapeutics AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (NAS:CRSP) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

CRSP:Mexico

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Executives

Samarth Kulkarni	officer: Chief Business Officer	C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Raju Prasad	officer: Chief Financial Officer	CRISPR THERAPEUTICS, INC., 105 W FIRST STREET, BOSTON MA 02127
Phuong Khanh Morrow	officer: Chief Medical Officer	C/O CRISPR THERAPEUTICS, 610 MAIN STREET, CAMBRIDGE MA 02139
Maria Fardis	director	C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Brendan Smith	officer: Chief Financial Officer	29 HARTWELL AVENUE, LEXINGTON MA 02421
Michael John Tomsicek	officer: Chief Financial Officer	28 OVERLOOK DRIVE, BEDFORD MA 01730
Bolzon Bradley J Phd	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Rodger Novak	director, officer: Chief Executive Officer	C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Harold Edward Fleming	director	C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Lawrence Otto Klein	officer: Chief Business Officer	C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET 7TH FLOOR, CAMBRIDGE MA 02139
James R. Kasinger	officer: General Counsel and Secretary	C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET, CAMBRIDGE MA 02139
Tony W Ho	officer: See Remarks	CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Douglas A Treco	director	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Pablo J Cagnoni	director	ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Katherine A High	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104